KEYNOTE-B49

1. 03:22
   ESMO 2026 现场信号

   #ScienceLink #Madrid2026 #ESMO26 #KEYNOTEB49 #CancerDeMama

1. 22:36
   ESMO 2026 现场信号

   STATISTICALLY POSITIVE. CLINICALLY THIN.
2. 19:18
   中文产业新闻

   KEYNOTE-B49三期结果显示帕博利珠单抗联合化疗显著延长PD-L1阳性HR+/HER2-晚期乳腺癌一线PFS

   KEYNOTE-B49三期主要分析显示，帕博利珠单抗联合化疗显著延长PD-L1阳性、HR+/HER2-晚期乳腺癌患者一线治疗的无进展生存期（PFS）。Hope Rugo教授在ESMO 2026大会上报告了研究结果。

3. 16:52
   ESMO 2026 现场信号

   #ESMO26 @myESMO #ESMOAmbassords new data from Keynote-b49 👇🏼
4. 15:47
   ESMO 2026 现场信号

   KEYNOTE-B49 at #ESMO26
5. 15:18
   ESMO 2026 现场信号

   🔥 KEYNOTE-B49 meets its primary endpoint, but benefit seems limited to few patients
6. 15:16
   ESMO 2026 现场信号

   PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> ht
7. 15:15
   ESMO 2026 现场信号

   Another reminder that immunotherapy is not a universal solution.
8. 15:05
   ESMO 2026 现场信号

   After so much effort to bring immunotherapy into HR+/HER2− mBC, KEYNOTE-B49 raises a hard question: is this worth it? A 0.7-month median PFS gain and no demonstrated OS benefit. We
9. 14:57
   ESMO 2026 现场信号

   KEYNOTE-B49 highlights an important distinction:
10. 14:54
    ESMO 2026 现场信号

    KEYNOTE-B49 presented by @hoperugo at #ESMO26
11. 14:52
    ESMO 2026 现场信号

    For my breast oncology colleagues:
12. 14:52
    ESMO 2026 现场信号

    One question I would ask the KEYNOTE-B49 investigators:
13. 14:51
    ESMO 2026 现场信号

    KEYNOTE-B49 raises a familiar oncology dilemma:
14. 14:49
    ESMO 2026 现场信号

    📌 Proffered paper 2: Breast cancer, early and advanced stage
15. 14:48
    ESMO 2026 现场信号

    Could PD-L1 selection be the real story in KEYNOTE-B49?
16. 14:48
    ESMO 2026 现场信号

    An important question for KEYNOTE-B49 at #ESMO26:
17. 14:45
    ESMO 2026 现场信号

    #ESMO26 | KEYNOTE-B49 – Phase III
18. 14:44
    ESMO 2026 现场信号

    KEYNOTE-B49
19. 14:44
    ESMO 2026 现场信号

    今回の注目試験の一つ、PD-L1(CPS>1) HR+/HER2ーの化学療法へのペムブロ上乗せをみたKEYNOTE-B49。
20. 14:42
    ESMO 2026 现场信号

    Where does KEYNOTE-B49 fit in today’s rapidly evolving breast cancer landscape?
21. 14:40
    ESMO 2026 现场信号

    KEYNOTE-B49 at #ESMO26 raises a fundamental question:
22. 14:30
    ESMO 2026 现场信号

    #ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEY
23. 14:30
    ESMO 2026 现场信号

    📢 #ESMO26 concomitant paper - Pembrolizumab plus chemotherapy for HR+/HER2− PD-L1‒positive advanced breast cancer: final analysis of the phase 3 KEYNOTE-B49 Study.
24. 14:24
    ESMO 2026 现场信号

    Starting with breast cancer at #ESMO26. KEYNOTE-B49 asks whether pembrolizumab + chemotherapy can improve outcomes in HR+/HER2− advanced disease. I’m particularly interested in PD-
25. 13:53
    ESMO 2026 现场信号

    Live from #ESMO26 Madrid with @TargetedOnc!
26. 06:27
    ESMO 2026 现场信号

    #ESMO26 | KEYNOTE-B49

1. 05:00
   ESMO 2026 现场信号

   🚨6 breast cancer trials to watch at #ESMO26 from leading voices including @ErikaHamilton9 @HundalJasmin and Nusrat Jahan, MD 🔗https://www.cancernetwork.com/view/from-keynote-b49-to

当前热度 102·可比范围峰值 136（10月24日 17:00）·近 24 小时可比范围变化 +2336%·当前参与者 18

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。